Clinical Trials on Neovascular Age-related Macular Degeneration (NVAMD) in Czechia

Total 44 results

Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
Sylentis, S.A.

Recruiting

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

Czechia, Slovakia, Poland
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

Spain, Korea, Republic of, Czechia, Japan, Singapore, United States, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Portugal, Bulgaria, Latvia, Canada, Hungary, Arge... and more
Bioeq GmbH

Completed

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration (MAGELLAN-AMD)

Neovascular Age-related Macular Degeneration

Bulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
PanOptica, Inc.

Completed

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

Neovascular Age-related Macular Degeneration

United States, Czechia, United Kingdom, Hungary, Latvia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (OCTAVE)

Neovascular Age-related Macular Degeneration

Germany, Turkey, Austria, Canada, Czechia, United Kingdom, Hungary, Italy, Lithuania, Guatemala, France, Ireland, Argentina, Portugal, Spain, Sweden, Greece, Switzerland, Slovakia, Finland, Netherlands, Colombia, Mexico, Panama
Opthea Limited

Completed

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Neovascular Age-related Macular Degeneration

United States, Czechia, France, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom
Sam Chun Dang Pharm. Co. Ltd.

Completed

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
Sandoz

Completed

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (Mylight)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, Czechia, Australia, Austria, France, Germany, Hungary, Israel, Japan, Latvia, Lithuania, Poland, Portugal, Slovakia, Spain
Opthea Limited

Recruiting

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

Neovascular Age-related Macular Degeneration

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Republic of, Latvia, Malaysia, Poland, Spain, Thailand, Ukraine, United Kingdom
Opthea Limited

Active, not recruiting

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (COAST)

Neovascular Age-related Macular Degeneration

United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Philippines and more
Chengdu Kanghong Biotech Co., Ltd.

Terminated

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
Amgen
Parexel

Completed

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Spain, United States, Czechia, Serbia, Israel, Canada, Germany, Japan, Hungary, Poland, Korea, Republic of, Estonia, Hong Kong, Italy, Latvia, Lithuania, Mexico, Slovakia
Novartis Pharmaceuticals

Completed

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (TALON Ext)

Neovascular Age-related Macular Degeneration

United States, Czechia, Italy, Taiwan, Australia, Israel, Belgium, France, Spain, Germany, Korea, Republic of, Portugal, Sweden, Netherlands, Malaysia, Switzerland
Hoffmann-La Roche

Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER)

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Germany, Croatia, Japan, United Kingdom, Spain, United States, Italy, Switzerland, Canada, France, Australia, Singapore, Israel, Puerto Rico, United Arab Emirates, Bulgaria, Chile, Czechia
Bayer

Terminated

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration (DREAM)

Macular Degeneration

Hong Kong, Korea, Republic of, United States, Canada, Switzerland, Spain, Japan, Italy, Czech Republic, Australia, Austria, Slovakia, Germany, Hungary, Israel, Chile, France, Colombia
University Hospital Hradec Kralove

Unknown

Treatment of AMD With Rheohemapheresis /RHF/ (TARHF)

Age Related Macular Degeneration

Czech Republic
Allergan
Molecular Partners AG

Terminated

Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

Wet Age-Related Macular Degeneration

Switzerland, France, Czech Republic
Pfizer

Completed

Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice

Age-related Macular Degeneration

Czechia
Bioeq GmbH

Completed

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration (COLUMBUS-AMD)

Age-related Macular Degeneration (AMD)

France, Italy, Poland, Russian Federation, Spain, United Kingdom, Germany, Hungary, Ukraine, Austria, Czechia, Israel
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration

Korea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
Shanghai Henlius Biotech

Active, not recruiting

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Age Related Macular Degeneration

United States, Singapore, Spain, Germany, Slovakia, China, Hungary, Australia, Bulgaria, Poland, Latvia, Czechia, France, Italy, Serbia
Alvotech Swiss AG

Active, not recruiting

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (ALVOEYE)

Neovascular (Wet) AMD

Slovakia, Czechia, Georgia, Japan, Latvia
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Italy, Canada, Switzerland, United States, United Kingdom, Austria, Belgium, Brazil, Czechia, Estonia, Latvia, Poland, Slovakia
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Age-Related Macular Degeneration

France, Israel, Italy, United States, Spain, Portugal, Germany, Austria, Canada, Czechia, Estonia, Latvia, Poland, Slovakia, Australia, Hungary, Croatia, Argentina, Finland, Brazil, Colombia, Norway
Oraya Therapeutics, Inc.

Completed

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD (INTREPID)

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Diseases | AMD | Wet AMD | Wet Age-Related Macular Degeneration

United Kingdom, Czech Republic, Austria, Germany, Italy
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

Geographic Atrophy Secondary to Age-related Macular Degeneration

United States, Netherlands, France, Israel, Germany, United Kingdom, Canada, Czechia, Australia, Spain, Italy, Argentina, Brazil, New Zealand, Poland
Apellis Pharmaceuticals, Inc.

Completed

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Geographic Atrophy

United States, France, Italy, Netherlands, Israel, Germany, United Kingdom, Spain, Australia, New Zealand, Poland, Brazil, Canada, Czechia
Astellas Pharma Global Development, Inc.

Active, not recruiting

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Age-Related Macular Degeneration | Geographic Atrophy

United States, Italy, Latvia, France, Israel, Germany, Spain, Hungary, Brazil, Canada, Argentina, Colombia, Croatia, Australia, Austria, Belgium, Czechia
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Geographic Atrophy

United States, France, Germany, Italy, Spain, Korea, Republic of, United Kingdom, Canada, Japan, Czechia, Australia, Latvia, Hungary, Slovakia
Apellis Pharmaceuticals, Inc.

Completed

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Geographic Atrophy

Italy, Germany, United States, Israel, United Kingdom, France, Canada, Czechia, Australia, Spain, Argentina, New Zealand, Poland, Brazil, Puerto Rico
Pfizer

Terminated

An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD (PERSPECTIVES)

Macular Degeneration | Age Related Macular Degeneration (AMD) | Choroidal Neovascularization (CNV)

Canada, Belgium, United Kingdom, France, Poland, Spain, Turkey, Czech Republic, Italy, Greece, Germany, Austria, Portugal, Denmark, Finland
ThromboGenics

Completed

A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)

Diabetic Retinopathy | Macular Edema

Czechia, Slovakia, Hungary
Bayer
Regeneron Pharmaceuticals

Completed

Intravitreal Aflibercept Injection in Vision Impairment Due to DME (VIVID-DME)

Diabetes Mellitus | Macular Edema

France, Japan, Australia, Austria, Poland, Czechia, Denmark, Germany, Hungary, Italy, Spain
Pfizer

Completed

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

Macular Edema Associated With Diabetes Mellitus

United States, Colombia, Australia, Germany, Italy, South Africa, Greece, France, Austria, United Kingdom, Denmark, India, Portugal, Brazil, Canada, Czechia, Netherlands, Switzerland
Oxurion

Completed

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema (KALAHARI)

Diabetes Mellitus | Diabetic Retinopathy | Diabetic Macular Edema

United States, France, United Kingdom, Spain, Germany, Italy, Slovakia, Czechia
Fovea Pharmaceuticals SA

Completed

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

Diabetic Macular Edema

United States, Australia, Belgium, Czech Republic, France, Germany, Israel, Italy, Poland, Spain
Pfizer

Terminated

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

Macular Edema, Diabetic

United States, Israel, Germany, Hungary, Bulgaria, Czech Republic, Moldova, Republic of, Poland, Romania
Kodiak Sciences Inc

Terminated

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLIMMER)

Diabetic Macular Edema

United States, Israel, France, Italy, Hungary, Poland, Puerto Rico, Czechia
Quark Pharmaceuticals

Completed

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) (MATISSE)

Diabetic Retinopathy | Diabetic Macular Edema | Choroidal Neovascularization

United States, Israel, United Kingdom, Belgium, Germany, Poland, Czech Republic
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus (RETAIN)

Diabetic Macular Edema

Belgium, United Kingdom, Netherlands, Ireland, Switzerland, Italy, Hungary, France, Spain, Portugal, Poland, Czech Republic, Greece
Regeneron Pharmaceuticals
Bayer

Active, not recruiting

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (PHOTON)

Type 2 Diabetes Mellitus | Diabetic Macular Edema | Type 1 Diabetes Mellitus

United States, Puerto Rico, Japan, United Kingdom, Canada, Czechia, Germany, Hungary

Clinical Trials on Neovascular Age-related Macular Degeneration (NVAMD) in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations